Combination therapy with chemotherapy for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (one targeted therapy and one immunotherapy) given with chemotherapy before and after surgery for stomach cancer that hasn't spread far. The goal is to see if this approach can improve outcomes for people with locally advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with adenocarcinoma in your stomach or where the stomach meets the food pipe.
- The cancer is locally advanced (has grown into nearby tissue but hasn't spread to distant organs) and you are eligible for surgery to remove it.
- You should be in reasonably good health (able to do light activity) and have adequate organ function.
- You have not had prior treatment for this cancer (no chemotherapy, radiation, or surgery).
- You don't have a history of blood clots, stroke, or major bleeding in the past few months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and FOLFOX chemotherapy) as the first treatment for advanced gastric (stomach) cancer. The goal is to see if this combination is safe and effective in shrinking tumors or slowing the cancer's growth.
This trial tests a new combination of drugs for advanced stomach cancer that has not been treated before. The goal is to see if adding a cholesterol-lowering drug to standard chemotherapy and immunotherapy can help shrink tumors and improve outcomes.
This study tests a combination of two medications (Sac-TMT and fruquintinib) as a second-line treatment for advanced stomach cancer. The goal is to see if this combination can help shrink tumors or slow the cancer's growth after a first treatment has stopped working.
This study tests a new combination of drugs (immunotherapy plus a targeted pill plus chemo) versus a standard combo (immunotherapy plus chemo) before surgery, for people with stage IV stomach cancer. The goal is to see if this approach can shrink the cancer enough to make it removable, potentially improving outcomes.
This study tests a combination of three drugs—fruquintinib, sintilimab, and XELOX chemo—for advanced stomach cancer. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.